

目 录

Content

头颈部肿瘤 (Head and Neck Cancer)	摘要 页码
A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677). [Abstract ID: LBA2 (163254)]	1
Gemcitabine plus cisplatin (GP) versus 5-FU plus cisplatin (FP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC): A randomized, open-label, multicenter, phase III trial. [Abstract ID: 6007 (164086)]	2
Induction docetaxel platinum 5-FU (TPF) followed by cetuximab-radiotherapy (cetux-RT) versus concurrent chemo-radiotherapy (CT/RT) in patients with N2b/c-N3 non operated stage III-IV squamous cell cancer of the head and neck (SCCHN): Results of the GORTEC 2007-02 phase III randomized trial. [Abstract ID: 6000 (170084)]	3
Further evaluations of nivolumab (nivo) versus investigator's choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141. [Abstract ID: 6009 (164984)]	4
Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC). [Abstract ID: 6011 (166094)]	5
肺癌 (Lung Cancer)	
A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study. [Abstract ID: 9012 (163941)]	6
Local consolidative therapy (LCT) to improve progression-free survival (PFS) in patients with oligometastatic non-small cell lung cancer (NSCLC) who receive induction systemic therapy (IST): Results of a multi-institutional phase II randomized study. [Abstract ID: 9004 (169928)]	7
Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC). [Abstract ID: 108 (167889)]	8
Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study. [Abstract ID: 9008 (167434)]	9
Bayesian randomized trial comparing intensity modulated radiation therapy versus passively scattered proton therapy for locally advanced non-small cell lung cancer. [Abstract ID: 8500 (168506)]	10

E1505: Adjuvant chemotherapy +/- bevacizumab for early stage NSCLC—Outcomes based on chemotherapy subsets. [Abstract ID: 8507 (166472)]	11
Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC). [Abstract ID: LBA8505 (162941)]	12
CONVERT: An international randomised trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS). [Abstract ID: 8504 (165387)]	13

乳腺癌 (Breast Cancer)	
A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. [Abstract ID: LBA1 (164642)]	14
Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA). [Abstract ID: 512 (165547)]	15
PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC). [Abstract ID: 507 (165131)]	16
Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE). [Abstract ID: 500 (166834)]	17
Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin. [Abstract ID: LBA503 (162159)]	18
Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative breast cancer. [Abstract ID: 1000 (166500)]	19
Ten-year survival results of ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node (Alliance). [Abstract ID: 1007 (170337)]	21
A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01). [Abstract ID: 1005 (170268)]	22
Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II	

results. [Abstract ID: LBA509 (166552)]	23
--	----

消化系统肿瘤 (Gastrointestinal Cancer)	
Impact of primary (1 ^o) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). [Abstract ID: 3504 (161936)]	24
Randomised phase III study of stenting as a bridge to surgery in obstructing colorectal cancer—Results of the UK ColoRectal Endoscopic Stenting Trial (CREST). [Abstract ID: 3507 (169602)]	25
The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers. [Abstract ID: 3511 (169716)]	26
FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study—Prodige 14 – accord 21 (METHEP-2), a unicancer GI trial. [Abstract ID: 3512 (168547)]	27
NCI9673: A multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA). [Abstract ID: 3503 (169985)]	28
FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma. [Abstract ID: LBA4001 (164788)]	29
Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)- CALGB 80802 (Alliance). [Abstract ID: 4003 (171166)]	30
NETTER-1 phase III: Efficacy and safety results in patients with midgut neuroendocrine tumors treated with ¹⁷⁷ Lu-DOTATATE. [Abstract ID: 4005 (170054)]	31
A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: First results from the CRITICS study. [Abstract ID: 4000 (165706)]	32
ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. [Abstract ID: LBA4006 (162546)]	33

泌尿系统肿瘤 (Genitourinary Cancer)	
Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate	

cancer (mCRPC): A three-arm phase III study (FIRSTANA). [Abstract ID: 5006 (166318)]	34
Phase III non-inferiority study of cabazitaxel (C) 20 mg/m ² (C20) versus 25 mg/m ² (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D). [Abstract ID: 5008 (169889)]	35
A randomized phase III trial between adjuvant docetaxel and surveillance after radical prostatectomy for high risk prostate cancer: Results of SPCG12. [Abstract ID: 5001 (166934)]	36
A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. [Abstract ID: 5003 (165234)]	37
Quality of life (QOL) analysis from CHAARTED: Chemohormonal androgen ablation randomized trial in prostate cancer (E3805). [Abstract ID: 5004 (171187)]	38
Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC). [Abstract ID: 4506 (167275)]	39
Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1. [Abstract ID: LBA4500 (170759)]	40
Limited versus extended pelvic lymphadenectomy in patients with bladder cancer undergoing radical cystectomy: Survival results from a prospective, randomized trial (LEA AUO AB 25/02). [Abstract ID: 4503 (168539)]	41

妇科肿瘤 (Gynecologic Cancer)	
Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis. [Abstract ID: 5501 (166142)]	42
Performance characteristics and stage distribution of invasive epithelial ovarian/tubal/peritoneal cancers in UKCTOCS. [Abstract ID: 5507 (170021)]	43
OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC). [Abstract ID: LBA5503 (168863)]	44
Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer (PRROC): The GCIG symptom benefit study (SBS). [Abstract ID: 5508 (167372)]	45

白血病、骨髓增生异常综合征、异体移植 (Leukemia, Myelodysplastic Syndromes, and	
---	--

Allotransplant)	
Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients \geq 65 years ineligible for standard induction therapy. [Abstract ID: 7009 (168695)]	46
Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML. [Abstract ID: 7008 (170782)]	47
Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. [Abstract ID: 7000 (165504)]	48
Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib: Results from the ENESTFreedom study. [Abstract ID: 7001 (166320)]	49

淋巴瘤和浆细胞瘤 (Lymphoma and Plasma Cell Dyscrasia)	
Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or no maintenance in patients with diffuse large B-cell lymphoma: Results from a HOVON-Nordic Lymphoma Group study. [Abstract ID: 7504 (164161)]	50
A phase 2 trial of ABVD followed by brentuximab vedotin consolidation in limited stage non-bulky Hodgkin lymphoma. [Abstract ID: 7508 (165119)]	51
A prospective, multicenter, randomized study of anti-CCR4 monoclonal antibody mogamulizumab (moga) vs investigator's choice (IC) in the treatment of patients (pts) with relapsed/refractory (R/R) adult T-cell leukemia-lymphoma (ATL). [Abstract ID: 7501 (167138)]	52
PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL). [Abstract ID: 7506 (163467)]	53
Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). [Abstract ID: 7503 (169547)]	54
Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study. [Abstract ID: LBA4 (172609)]	55
Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial).	56

[Abstract ID: 8000 (167867)]	
Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS). [Abstract ID: 8001 (168948)]	57
A phase Ib dose escalation trial of isatuximab (SAR650984, anti-CD38 mAb) plus lenalidomide and dexamethasone (Len/Dex) in relapsed/refractory multiple myeloma (RRMM): Interim results from two new dose cohorts. [Abstract ID: 8009 (164111)]	58
Genetic plasma cell signatures in high-risk smoldering myeloma versus multiple myeloma patients. [Abstract ID: 8003 (170498)]	59

黑色素瘤/皮肤癌 (Melanoma/Skin Cancers)	
Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. [Abstract ID: 9503 (167363)]	60
Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients (pts) with advanced melanoma (MEL) (CheckMate 067). [Abstract ID: 9505 (165588)]	61
Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort. [Abstract ID: 9506 (167092)]	62
Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006. [Abstract ID: 9504 (165198)]	63
Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. [Abstract ID: 9502 (168199)]	64

患者和生存者护理 (Patient and Survivor Care)	
Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants in SWOG clinical trials. [Abstract: 10001 (162825)]	65
Benefits of physician orders for scope of treatment (POST) forms on end-of-life care in cancer patients: Insights from the West Virginia registry. [Abstract: 10006 (163730)]	66
A URCC NCORP nationwide randomized controlled trial investigating the effect of exercise on chemotherapy-induced peripheral neuropathy in 314 cancer patients.	

<i>[Abstract: 10000 (170470)]</i>	67
Randomized trial of early integrated palliative and oncology care. <i>[Abstract: 10003 (166829)]</i>	68
Placebo-controlled phase III study comparing dexamethasone on day 1 to on day 1-3 with NK1 receptor antagonist and palonosetron in high emetogenic chemotherapy. <i>[Abstract: 10019 (161961)]</i>	69

发展治疗 (DEVELOPMENTAL THERAPEUTICS)	
Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors. <i>[Abstract ID: 2500 (164336)]</i>	71
Phase I study of sapacitabine and seliciclib in patients with advanced solid tumors. <i>[Abstract ID: 2503 (171083)]</i>	72
Checkmate 032: Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC). <i>[Abstract ID: 100 (163413)]</i>	73
Programmed death-1 blockade in mismatch repair deficient cancer independent of tumor histology. <i>[Abstract ID: 3003 (170754)]</i>	74
CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. <i>[Abstract ID: 3001 (163524)]</i>	75